HLA-A*24:02-restricted Up-regulated in lung cancer 10 peptide epitope (HLA-A*2402/URLC10)

The HLA-A*2402-presented URLC10 peptide epitope is a tumor-associated antigen complex utilized in the development of precision immunotherapies. URLC10 (Up-regulated in lung cancer 10) is a member of the cancer-testis antigen family, characterized by high expression in various solid tumors—such as non-small cell lung cancer, esophageal, and gastric cancers—and restricted expression in normal tissues, primarily the testis (Suda et al., 2004, Oncogene). The specific epitope is generated when URLC10 protein is processed intracellularly and its peptide fragments are presented on the cell surface by the HLA-A*24:02 MHC Class I molecule (Suda et al., 2007, Cancer Sci). This complex serves as a critical recognition site for CD8+ cytotoxic T lymphocytes (CTLs). Therapeutic interventions, including peptide vaccines like URLC10-177 and TCR-T cell therapies, aim to stimulate or provide a robust immune response against cells displaying this epitope (Hazama et al., 2014, J Cancer Res Clin Oncol). Given the high frequency of the HLA-A*24:02 allele in Asian populations, this target is particularly relevant for regional oncology drug development. Clinical monitoring often involves assessing HLA status and URLC10 expression levels to ensure patient eligibility and treatment efficacy (Watanabe et al., 2014, Cancer Sci).

Other names

URLC10-177 peptideURLC10 epitopeHLA-A*24:02/URLC10-177Up-regulated in lung cancer 10 peptide

Induction of peptide-specific cytotoxic T lymphocytes (CTLs) that recognize and lyse tumor cells presenting the URLC10 peptide on HLA-A*24:02.